PR-C
Use of Cytoflavin Solution at the Time of Early Rehabilitation in Patients With Post-intensive Care Syndrome Who Underwent Ischemic Stroke
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT04194229/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 60 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (01.2021) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 33
Критерии включения
- Men and women aged 18 years and above;
- Patients who underwent ischemic stroke;
- The period from the development of ischemic stroke is not less than 12 and not more than 28 days;
- Staying in intensive care unit for no less than 72 hours;
- Diagnosed post-intensive care syndrome (PICS);
- Functional status assessed using the modified Rankin scale amounts to 4-5;
- Gravity gradient of 20° to 40° upon inclusion in observational non-interventional program
Критерии невключения
- Vegetative state;
- Mechanical ventilation lasting more than 72 hours after the development of ischemic stroke;
- Surgical treatment for cerebral stroke (decompressive craniectomy; thromboextraction etc.);
- Premorbid (before the development of ischemic stroke) level of functional activity assessed using the modified Rankin scale amounts to 4 or 5;
- Signs of increasing neurological deficit or enlargement of hypoperfusion zones on CT scans within 24 hours before inclusion in observational non-interventional program;
- Level of consciousness ≤ 5 according to Glasgow Coma Scale and/or ≥ 1 according to Richmond Agitation-Sedation Scale (RASS);
- Behavioral Pain Scale (BPS) or Visual Analogue Scale assessment score of more than > 0 at the moment of inclusion;
- Systolic blood pressure < 90 and > 180 mm Hg;
- Diastolic blood pressure ≥ 110 mm Hg;
- Mean ABP < 60 mm Hg;
- Clinical and/or electrocardiographic signs of acute coronary syndrome (including de novo ST elevation or depression, negative T-waves amplitude formation and buildup, formation of pathological Q-wave, increase in the level of markers of myocardial injury - troponin T or I, creatine phosphokinase-MB, LDH-1), or diagnosed acute myocardial infarction occurring within a month before inclusion in observational program;
- Acute heart arrhythmias;
- Heart rate (HR) < 60 or > 100 per minute;
- Spontaneous respiration rate (RR) < 10 or > 30 per minute;
- Arterial oxygen saturation (SpO2) < 90 %;
- Venous serum glucose level ≤ 4 mmol/L;
- Axillary body temperature ≥ 38.5 °C;
- Hematocrit ≤ 30 %;
- Level of hemoglobin ≤ 80 g/l;
- Serum total protein ≤ 55 g/l;
- Positive passive leg raising test (PRL-test);
- Acute heart failure;
- Acute respiratory failure;
- Acute kidney injury;
- Acute liver cell failure;
- Congestive heart failure;
- Chronic respiratory failure, stage greater than I;
- Chronic kidney disease with estimated glomerular filtration rate using Cockcroft-Gault formula < 60 ml/min/1.73 m2;
- Clinically significant deviations in the results of complete blood count, blood chemistry, common urine analysis, except those that are acceptable according to other non inclusion criteria;
- Purulent-inflammatory diseases at any location;
- Refuse of the patient to undergo verticalization or exercise sessions;
- Use of medicinal products belonging to the pharmaceutical therapeutic category of metabolic drugs at the time of inclusion in observational non-interventional program, as well as plans for their use during study;
- Plans for use of physical rehabilitation methods other than verticalization and cycling exercise sessions during the course of the program.
Источник: ClinicalTrials.gov, NCT04194229 · запись обновлена в реестре 19 июля 2024.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 5
- Median time to achieving gravity gradient of 90° — 10 days
Цель исследования
Objective - to assess the effect of Cytoflavin® and its tolerability within the integrated program of rehabilitation of patients who underwent ischemic stroke
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04194229 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.